Corvus Pharmaceuticals, Inc.
Corvus Pharmaceuticals, Inc. (CRVS) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
crvs · pe ratio · data through Jun 9, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMInsufficient PE history data (fewer than 3 valid fiscal years).
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Corvus Pharmaceuticals, Inc.You CRVS | $938M | N/A | — | -$0.49 |
 Absci Corporation ABSI | $1.0B | N/A | — | -$0.84 |
 Akebia Therapeutics, Inc. AKBA | $251M | N/A | — | -$0.02 |
 Compass Therapeutics, Inc. CMPX | $279M | N/A | — | -$0.42 |
 Gossamer Bio, Inc. GOSS | $39M | N/A | — | -$0.75 |
 KalVista Pharmaceuticals, Inc. KALV | $1.4B | N/A | — | -$3.23 |
 Olema Pharmaceuticals, Inc. OLMA | $917M | N/A | — | -$1.87 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Corvus Pharmaceuticals, Inc. (CRVS) measures how much investors pay for each dollar of the company's trailing earnings. CRVS's current PE ratio of N/A is calculated by dividing its stock price of $11.15 by its TTM earnings per share of -$0.49.
Frequently asked questions
CRVS pe ratio · 6 questionsCRVS's current PE ratio is N/A as of 2026-06-09, based on a stock price of $11.15 and TTM EPS of -$0.49. Data sourced from Financial Modeling Prep via CRVS's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Corvus Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09